Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01528787 · ClinicalTrials.gov registry record · Phase 2
Study of AR-13324 in Patients With Elevated Intraocular Pressure
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT01528787 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 85 participants.
The verdict
NCT01528787, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.
Interventions
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG AR-13324 Ophthalmic Solution 0.04%
- DRUG AR-13324 Ophthalmic Solution 0.01%
- OTHER AR-13324 Ophthalmic Solution Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01528787
The ClinicalTrials.gov registry entry for NCT01528787 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AR-13324 Ophthalmic Solution 0.02% is the first listed.
NCT01528787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01528787 about?
NCT01528787 is a clinical study titled "Study of AR-13324 in Patients With Elevated Intraocular Pressure". In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular...
What is the current status of trial NCT01528787?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2012-03. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01528787?
The interventions under investigation include: AR-13324 Ophthalmic Solution 0.02% (DRUG), AR-13324 Ophthalmic Solution 0.04% (DRUG), AR-13324 Ophthalmic Solution 0.01% (DRUG), AR-13324 Ophthalmic Solution Vehicle (OTHER).
Who is sponsoring clinical trial NCT01528787?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.